Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

105.77 +0.90 (+0.86%)
Official Closing Price Updated: 1:10 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
42 43 Next >
Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside
JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers... 
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report
Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years. 
Via Benzinga
Topics Workforce
Exposures Layoff
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These companies' prospects look secure. 
Via The Motley Fool
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Benzinga 
Via Benzinga
Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it  
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Price Over Earnings Overview: Novartis
Via Benzinga
Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic  
Via Benzinga
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS). 
Via Benzinga
AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC
AMC Entertainment (AMC) stock is a hot topic on Friday after the movie theater chain's CEO teased that new products are on the way. 
Via InvestorPlace
Why Is Canopy Growth (CGC) Stock Up 14% Today?
Canopy Growth (CGC) stock is rising higher on Friday after the cannabis company announced it won't fund BioSteel Sports Nutrition any longer. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff
Novartis (NVS) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz. 
Via InvestorPlace
Instacart Mulls IPO Price Hike After Arm's Stellar Debut, UAW Launches Historic Simultaneous Strike, China Sanctions Lockheed Martin & Northrop Grumman Concerning Taiwan Arms Sales: Today's Top Stories
Wall Street Journal 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders  
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Benzinga Qualcomm Announces Chip Supply Agreement With Apple 
Via Benzinga
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
AI 2.0 is Here: How to Invest in a Generational Opportunity
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it. 
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Supply Chain
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.